Weight change study for people with HIV switching to DOR/3TC/TDF
Part of Hormones & metabolism, Infections clinical trials.
This study tests whether switching your HIV medication to a combination called DOR/3TC/TDF can help with weight changes that started after taking another type of HIV drug (integrase inhibitor). It is for people who have gained weight unintentionally and want to see if a different medication helps manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HIV and your viral load has been undetectable for at least 48 weeks.
- You are currently taking Biktarvy, Triumeq, or DTG+TDF/FTC and have not had treatment failure with these drugs.
- You have a body mass index (BMI) of 25 or higher, meaning you are considered overweight.
- You gained more than 10% of your body weight without trying within 1–3 years of starting your current HIV medicine, and no other cause explains it.
- You agree to stick with the assigned HIV medication during the study and have no plans to start weight loss drugs or major diet/exercise changes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This trial tests if switching to a two-drug combination of dolutegravir and lamivudine is safe and effective for transgender women who already have undetectable HIV levels on a three-drug regimen. It aims to simplify treatment and reduce side effects.
This study sees if it's safe to switch your current HIV medication to a two-pill combo (dolutegravir and lamivudine) if you are also taking medication for opioid addiction. It aims to make treatment simpler and more convenient.
This trial compares two different HIV treatment plans: keeping you on a 2-drug regimen versus switching to a 3-drug regimen. It’s designed for people whose HIV is well controlled and looks at whether the switch is safe and effective.
This study collects data from HIV patients who start treatment with a two-drug combination of dolutegravir and lamivudine, either as their first treatment or after switching from a three-drug regimen.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.